A new targeted anti-tumoral therapy based on the concept of dependence receptors

NETRIS est accrédité par Lyonbiopôle

Identity card

Global budget: 3900 k€

Public funding: 1 386 k€

Public funders: ANR, Agence Nationale de la Recherche

Call for projects: ANR (ANR2008 - BIOTECS)

Year start: 2008

Completed project (2012-02)

Accredited by the French competitiveness cluster Lyonbiopôle

Strategic business area: Human Medicines

Application fields: Oncology

Technological approaches / Keywords: Functional Screening / Drug discovery, Immunotherapy

Stage of development at the beginning of the project: Discovery


The new family of dependence receptors share the ability to trigger cell death in the absence of their respective ligand. This property has been shown to confer these receptors a tumor suppressor activity. A selective advantage for a tumor to develop is to inactivate this dependence receptor pathway. NETRIS Pharma, created in 2008, develop a very new class of antitumoral targeted therapeutics molecules based on the dependence receptor concept. The company will take the new therapeutics molecules from the proof of concept and will bring them to pre-clinical or clinical phases.


The objective of the Netris project is to develop a very new class of anti-tumoral targeted therapeutics molecules based on the dependence receptor concept that has been discovered by the CNRS UMR5238. The project has emerged by the proof of concept that a molecule able to interfere with the interaction between one pair ligand/dependence receptors, reintroduce the death of the metastatic breast cells. This molecule is the first «hit» of a whole panel of other molecules targeting the dozen of other pairs dependence receptor/ligand discovered by the academic laboratory and linked to cancer development.

Innovative assets
Actual results

Innovative assets

New therapeutic approach in oncotherapy